All 20 patients with high-risk smoldering multiple myeloma showed results with Carvykti in a Dana-Farber Cancer Institute study, researchers reported.
The dataset is small, but the context gives it weight. Smoldering multiple myeloma sits between a benign precursor state and active disease; patients with the high-risk form face elevated progression risk but don’t currently qualify for treatment under standard clinical guidelines. Dana-Farber’s data puts intervention before that threshold on the table.
Carvykti (ciltacabtagene autoleucel), the BCMA-targeting CAR-T therapy from Johnson & Johnson and Legend Biotech, holds FDA clearance for relapsed or refractory multiple myeloma. Extending it to smoldering disease, before a patient has received any standard-line treatment, would represent a direct earlier-line expansion.
If this data survives larger trials, the question for regulators and oncologists becomes direct: where does CAR-T therapy belong in the myeloma treatment sequence? Currently, the answer is late-line, after other treatments have failed. Results in all 20 smoldering patients suggest that answer could shift.
No regulatory timeline was announced from the Dana-Farber presentation.
Sarah Chen